-
-
-
-
-
-
-
Abbott Labs (ABT) PT Lowered to $120 at Stifel Following Q1 Results
-
-
-
-
-
-
-
Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
-
-
-
-
-
-
-
Abbott Labs (ABT) PT Lowered to $119 at Leerink Partners
-
-
-
-
-
-
-
UBS Reiterates Buy Rating on Abbott Labs (ABT): Modelling ~6% Dx growth TOT in 2026
-
-
-
-
-
-
-
Abbott reportedly nearing deal for Exact Sciences
-
-
-
-
-
-
-
Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook
-
-
-
-
-
-
-
Ancora Nominates Four Highly Qualified, Independent Director Candidates and Urges Orderly CEO Succession at Elanco Animal Health
-
1,169,815 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

